Comparing Guided Therapeutics (GTHP) & Its Competitors

Guided Therapeutics (OTCMKTS:GTHP) is one of 78 public companies in the “Electromedical equipment” industry, but how does it compare to its rivals? We will compare Guided Therapeutics to similar companies based on the strength of its analyst recommendations, earnings, institutional ownership, valuation, risk, dividends and profitability.

Risk & Volatility

Guided Therapeutics has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Guided Therapeutics’ rivals have a beta of 16.35, suggesting that their average share price is 1,535% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Guided Therapeutics and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guided Therapeutics	0	0	0	0	N/A
Guided Therapeutics Competitors	287	826	2136	109	2.62

As a group, “Electromedical equipment” companies have a potential upside of 2,855.87%. Given Guided Therapeutics’ rivals higher probable upside, analysts plainly believe Guided Therapeutics has less favorable growth aspects than its rivals.

Institutional & Insider Ownership

9.7% of Guided Therapeutics shares are held by institutional investors. Comparatively, 44.3% of shares of all “Electromedical equipment” companies are held by institutional investors. 66.8% of Guided Therapeutics shares are held by insiders. Comparatively, 15.1% of shares of all “Electromedical equipment” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Guided Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Guided Therapeutics	N/A	N/A	-138.23%
Guided Therapeutics Competitors	-299.08%	-83.96%	-27.59%

Earnings & Valuation

This table compares Guided Therapeutics and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Guided Therapeutics	$100,000.00	-$3.49 million	-5.33
Guided Therapeutics Competitors	$991.32 million	$83.13 million	9.81

Guided Therapeutics’ rivals have higher revenue and earnings than Guided Therapeutics. Guided Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Guided Therapeutics rivals beat Guided Therapeutics on 7 of the 10 factors compared.

Guided Therapeutics Company Profile

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.